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1. Introduction 
 
1.1 Gene delivery 
 
Gene therapy is based on the addition of genes into the genome of the cells of 
interest to correct genetic defects or mediate the expression of specific proteins. To 
make this possible, the gene of interest needs to be delivered into target cells using a 
delivery system. Friedmann and Roblin describe already in 1972 that gene therapy 
could ameliorate some human genetic diseases in the future ([1]).  
To date there are more than 1600 clinical trials based on gene therapy, most of them 
for cancer diseases ( http://www.wiley.com//legacy/wileychi/genmed/clinical/). 
 
Figure 1.1: Clinical trials based on gene therapy 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/) 
The most common used vectors for clinical trials are viral vectors because of their 
high transfection ability (http://www.wiley.com//legacy/wileychi/genmed/clinical/),  
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but serious concerns exist that their use can cause a strong immune response ([2], 
[3]) or lead to insertional mutagenesis ([4]).  
To overcome this problem, non viral gene delivery systems might be used. 
Hydrodynamic delivery, where a large volume of a DNA solution is rapid injected into 
the tail vein of a mouse, can lead to a transfection of approximately 30-40% of the 
hepatocytes by a single injection ([5]). Because of the mechanism of the 
hydrodynamic delivery no agent is needed to protect the DNA from degradation by 
serum and extracellular nucleases. Alternatively non viral vector formulations can be 
used as a kind of “transport vehicle” to the targeted cell.  
Cationic lipids are amphiphilic structures which are able to self assemble into lamellar 
vesicular structures. In aqueous solution their positively charged head-groups 
condensate with the negatively charged nucleic acid and built spherical structure 
which is protecting the nucleic acid from degradation ([6]). Cationic polymers show as 
well the potential to condense nucleic acids. Though they also can cause 
inflammatory response ([7]), there are actually many approaches to overcome these 
([8], [9], [5]). Ruß et al ([10]) have synthesized a biodegradable polypropylenimine 
dendrimer generation 3 modified with branched oligoethylenimine 800Da (G3-HD-
OEI) and applied it in vitro and in vivo. Is was shown that the G3HDOEI has an 
advantageous biocompatibility profile compared to the non biodegradable carriers 
linear polyethylenimine (LPEI) or branched polyethylenimine (BPEI). The improved 
biophysical and biological properties of G3-HD-OEI make it a very attractive vector 
for further in vivo experiments.  
It has been shown that not only the carrier may cause immune response, but also the 
plasmid DNA. Only one CpG-motif in the plasmid DNA can be sufficient to elicit an 
inflammatory response, whereas CpG-free pDNA does not ([11], [12]).  Novel CpG-
free plasmids were for this purpose cloned in our lab by Dr. Rudolf Haase and 
optimized for a stable transgene expression by ideal promoter/enhancer 
combinations (see PhD thesis Terese Magnusson, LMU). 
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1.2 Mouse tumor models 
 
Comparative genome studies found that the DNA- sequence of humans and mice 
show 85% similarity 
(http://www.ornl.gov/sci/techresources/Human_Genome/faq/compgen.shtml). Mice 
are a common species used for the investigation of potential drugs and recently a 
Knock Out Mouse project was launched so that there is a database of information 
that can be used for the development of novel therapeutic strategies 
(http://www.knockoutmouse.org/). A retrospective evaluation of the knockout 
phenotypes for the targets of the 100 best-selling drugs indicates that effects in these 
murine models of human disease correlates well with clinical drug efficacy ([13]). In 
cancer research, experimental tumors raised in mice are an important preclinical tool 
for the screening of new substances before clinical testing.  ([14]). There are different 
ways of developing murine tumor models. One of them is genetic engineering 
producing a transgenic mouse by the pronuclear injection of new genetic material into 
a single cell of the mouse embryo or a knock out mouse by modifying embryonic 
stem cells with a DNA construct containing DNA sequences homologous to the target 
gene and injecting them into blastocysts ([15], [16]) These methods are time 
consuming, high in cost, need well trained people and special equipment. 
Nevertheless, they are used as cancer disease models ([17], [18], [19]).Carcinogen 
induced tumor models are another possibility to create a tumor bearing mouse. They 
have been proven to be useful especially for the study of chemoprevention agents 
([20], [21]). Another method is to implant tumor material into the mice. It is lower in 
cost and easier to handle. Generally there are syngeneic mouse models, where the 
mice bear tumors originating from their own species, or xenografts, where 
immunosupressed mice bear tumors originating from humans. In both cases the 
tumor can be inoculated on different sites. (reviewed by [14]) 
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1.2.1 Syngeneic tumor models 
 
One of the first syngeneic tumor models used for the research of anticancer agents 
were the L1210 and P388 leukemias developed in 1948 resp. 1955 ([22], Dawe,C.J. 
and Potter,M. Morphologic and biologic progression of a lymphoid neoplasm of the 
mouse in vitro and in vivo, Am. J. Pathol., 33: 603, 1957.) Since then a lot of other 
syngeneic tumor models in mice were established. An advantage of this tumor 
models is that the host is fully immunocompetent, the tumor induction is mostly not 
immunogenic (reviewed by [14]), the host is readily available and, because of the 
long history of use, a strong baseline of drug response data is available  ([23]). The 
disadvantage of this model lies in its nature. Because the tumor cells are from murine 
origin, thus expressing murine homologues of possible human targets making them 
less suitable for targeted therapies.  
 
1.2.2 Xenograft models 
 
Subcutaneous xenogeneic models have been the mainstay of anticancer drug 
development over the last 25 years, mostly because they are better predictors of 
drug efficacy in human tumors. They are simple, reproducible and homogenous in 
their tumor histology and growth rates and there are many human cell lines available 
expressing a human target molecule opening the possibility of targeted drug and 
gene delivery (reviewed by [14]). The disadvantage of this of these models is that the 
stromal component is still rodent and the mice used for these models are 
immunodeficient ([23]).  
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1.2.3 Metastatic tumor models 
 
In subcutaneous tumors one has the opportunity to measure the tumor volume and 
calculate a tumor growth delay (or inhibition) comparing a treated with a non treated 
group. The big disadvantage of this tumor models is that the tumor is growing at an 
unnatural site. Therefore metastatic tumor models have been developed implanting 
the tumor cells via injecting them into the blood stream (intravenous or intracardiac 
injection) as a disseminated tumor model ([24], [25]) or injecting them in the 
orthotopic site were the tumor lines were derived from ([26], [27]). There are a few 
disadvantages in this tumor model. First surgeries for orthotopic tumor setting are 
often complex, and tumor growth and response is difficult to follow leading to the 
point, that the survival is the only parameter being measurable. That is the reason 
why animal experiments are often done by the conventional way of time-stacked 
sacrifice of animals for ex vivo molecular-biological assays which causes high animal 
numbers per experiment and does not allow us to follow the disease/treatment 
development in real time. This problem can be, at least partially, overcome by 
molecular imaging methods ([28], [29], [30]).   
 
 
 
1.3 Non invasive imaging 
 
1896 WC Roentgen described his “new kind of rays” ([31]) in Nature and discloses 
the possibility of non invasive imaging in human and animals. A variety of other 
methods have been established since his discovery. Based on classical X-Ray 
imaging, computed X-Ray tomography (CT) has been developed. Another approach 
is the magnetic resonance imaging (MRI) based on the magnetic properties of 
unpaired nuclear spins. Although the main field of use of these techniques is the  
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anatomic imaging when combined with contrast agents or with other imaging 
techniques like positron emission tomography (PET) or single photon emission 
computed tomography (SPECT), they can be used for molecular imaging too ([32], 
[33], [34]).   
Molecular imaging has been developed to follow different processes like 
biodistribution ([35]), enzyme activity ([36]), inflammation, tumor spreading and 
progress etc. at the cellular level. At sites of diseases, normal gene expression is 
alterated to distinct pathobiochemical expression ( [37]). Following gene expression 
(for example by monitoring a specific reporter gene) is one approach where imaging 
methods are valuable.  
 
1.3.1 Fluorescence imaging 
 
For fluorescence imaging a fluorochrome is excited, by e.g. laser diodes, operating at 
a frequency close to that of the detected light and the emitted fluorescent light is than 
detected by a CCD camera. GFP, a protein from the jellyfish Aqueorea victoria, is 
one of the best known proteins used for this purpose. Wild type GFP emits blue light 
which is a disadvantage with regard to autofluorescence of the non targeted tissue, 
and also the fluorescence signal of green emitting enhanced GFP (EGFP) can 
overlap with autofluorescence of tissue. The use of the near infra red fluoroprobes 
(like Cy5.5 or Cy7, Alexa 700 or 750) is therefore the better option because the 
absorption of haemoglobin  (a major absorber of visible light) absorbs light at lower 
wavelength. Zintchenko et al could show that near-intrared emitting CdTe quantum 
dots as labeling device for macromolecular drugs can be used for effective screening 
of biodistribution events and also could be, incorporated into quantoplexes, a 
promising assist in the development and improvement of new macromolecular drug 
formulations  ([35]). 
 
 
 
7 
 
Chapter 1: Introduction 
 
 
1.3.2 Bioluminescence imaging 
 
Bioluminescence refers to the enzymatic generation of visible light by living 
organisms. Light photons at wavelengths between 400 and 1000 nm can be 
converted using a CCD camera into an electronic signal. These signal intensities are 
correlating with the intensity of the incoming photons, and digitization of these data 
allowing us further processing of these data.  Luciferases are enzymes often used as 
transgene/reporter gene for bioluminescence imaging. The most common used 
luciferase is the Photinus pyralis luciferase from the North American firefly. This 
enzyme catalyses the transformation of its substrate -luciferin (  -(−)-2-(6′-hydroxy-
2′-benzothiazolyl) thiazone-4-carboxylic acid) into oxyluciferin in an ATP-dependent 
process, leading to the emission of light photons at a wavelength of about 560nm. 
([38]). Investigators have used Firefly Luciferase for the drug development against 
viral or bacterial diseases, ([39], [40], [41], reviewed by [38]) as well as for cancer 
research, where it was used to stably transfect tumor cells, which were thereafter 
inoculated, or as a reporter gene after intravenous  injection,  as a plasmid DNA 
complexed with a polyplex ([42], [43], [44], [45], [46]). In the last few years another 
luciferase has gained in interest for cancer research – the Gaussia Luciferase. Up to 
date it is the smallest known (19.9 kDa) and naturally secreted luciferase from the 
marine copepod Gaussia princeps. It is emitting light with a peak at 480nm and is 
therefore more susceptible to tissue absorption and scattering. It does not require 
ATP for the oxidation of its substrate coelenterazine. In contrast to Firefly Luciferase, 
it has flash kinetics reaching the maximum of activity within the first 10 seconds after 
addition of coelenterazine and drops over the course of 10 minutes significantly 
([47]). 
Tannous et al ([47]) could also show that the humanized Gaussia Luciferase has a 
200-fold higher bioluminescent signal intensity than the humanized Renilla Luciferase 
(Luciferase from the sea pansy Renilla reniformis, also using coelenterazine as 
substrate) and a comparable intensity with that from the humanized form of Firefly 
Luciferase in vivo. 
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1.4 Aim of the work 
 
The aim of this work was to establish a liver tumor metastases model in mice 
(syngeneic as well as xenogeneic), using luciferase as reporter gene, which could be 
used in further experiments for the development of novel defined and fully synthetic 
non viral gene (or siRNA) vectors for the delivery into tumor tissue allowing cancer 
treatment.  
Amirkhosravi et al ([48]) described a syngeneic tumor model where A/J mice were 
intravenously inoculated with Neuro2a, which led to the development of extensive 
liver metastases. For the experiments in this thesis the Neuro2a metastases model 
has been chosen, as our lab and others could show that subcutaneous Neuro2a 
tumors are accessible for intravenously applied synthetic gene delivery vectors 
([8],[64],[65]). 
It is known for colorectal cancer that hepatic metastases are the major cause of 
death in these patients ([49]). For this reason we aimed to establish in our lab a 
xenogeneic liver metastasis model using the LS174T human colon carcinoma cell 
line, where it is from the literature known that liver metastasis can be achieved by 
injecting tumor cells into the spleen ([49], [50], [51]). 
For the establishment of the metastatic tumor models we have stably transfected the 
tumor cell lines with Firefly Luciferase with the help of a lentiviral vector as a tool so 
that we had the possibility of tracking the cells via bioluminescent imaging. The tumor 
models achieved this way had to be compared also to tumor metastases achieved by 
inoculating wild type Neuro2a tumor cells, to ensure that their growth characteristics 
and spreading pattern stays the same. Gaussia Luciferase had been used as 
reporter gene to ensure that the tumor metastases are accessible for non viral gene 
delivery, enabling dual imaging - real time bioluminescent imaging of the stably 
Firefly Luciferase expressing tumor metastases and the via intravenous non viral 
gene delivery transfected tumor metastases within the same animal (Fig.1.2). 
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Fig. 1.2 Single and Dual Bioluminescent Imaging 
 
A) The mouse was inoculated with wild type tumor cells and transfected 
intravenously with a polyplex containing a plasmid encoding either for Firefly 
Luciferase or for Gaussia Luciferase and was then injected for the 
bioluminescent imaging either with d-luciferin or with coelenterazine according 
to the type of luciferase used for the transfection 
B) The mouse was inoculated with a stable Firefly Luciferase expressing cell line. 
Single bioluminescent imaging after d-luciferin injection is possible like in A). 
After intravenous transfection with a polyplex containing a plasmid encoding 
for Gaussia Luciferase, dual bioluminescent imaging is possible after 
intravenous injection of its substrate coelenterazine. 
 
 
 
 
A 
A 
B
B
B
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2. Material and Methods 
 
2.1 Material 
 
Materials were purchased / prepared as stated below 
 
2.1.1 Bacterial culture 
LB – medium   -     Bacto-Typton (AppliChem, Darmstadt, 
Germany) 10g 
- Yeast Extract (AppliChem, Darmstadt, 
Germany) 5g 
- NaCl (Merck Darmstadt, Germany) 5g 
- ad 1L with aqua bidest 
 
Zeocin     Invitrogen (Karlsruhe, Germany) 
 
2.1.2 Molecular biology 
 
2.1.2.1 Vector amplification 
EndoFree plasmid kit (giga)  Qiagen (Hilden, Germany) 
 
10x TBE electrophorese  - Tris base (SIGMA-Aldrich, Steinheim, Germany) 
buffer       108g      
- Boric acid (Merck, Darmstadt, Germany) 55g 
     - ad 700mL with aqua bidest 
     - 0,5M EDTA (SIGMA-Aldrich, Steinheim, Germany) 
   40mL 
- adjust with NaOH (VWR International, Darmstadt, 
  Germany) on pH 8 
- ad 1L with aqua bidest 
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Agarose    Invitrogen (Karlsruhe, Germany) 
 
GelRed Nucleic Acid Stain BIOTREND Chemikalien (Köln, Germany) 
 
DNA – Marker   New England BioLabs (Ipswich, U.S.A.) / Promega 
(Mannheim, Germany) 
 
 
2.1.2.2 Restriction Enzymes 
 
Nhe I     New England BioLabs (Ipswich, U.S.A.) / Promega 
(Mannheim, Germany) 
 
Bgl II     Promega 
(Mannheim, Germany) 
 
2.1.3 Cell culture 
 
Murine Neuroblastoma  LGC Standards (ATCC CCI – 131)  
Neuro2a cells 
 
Neuro2a Luc+ cells   Neuro2a cells stably expressing Photinus pyralis 
luciferase were constructed in our lab by Dr. Gelja 
Maiwald (LMU) 
 
Neuro2a lenti Luc cells  Neuro2a cells stably expressing a fusion protein of 
EGFP and Photinus pyralis luciferase were 
constructed in our lab by Arzu Cengizeroglu (LMU) 
by lentiviral transduction 
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LS174T CTP4 lenti Luc cells LS174T cells stably expressing a fusion protein of 
EGFP and Photinus pyralis luciferase were 
constructed in our lab by Arzu Cengizeroglu 
(LMU) by lentiviral transduction 
 
DMEM 1 g glucose   - DMEM, 4,5g Glucose/L, with L-Glutamin without 
  NaHCO3 (Biochrom, Berlin, Germany) 10,15g 
- NaHCO3  3,7g 
- ad 1L with aqua bidest 
 
GIBCO® RPMI Medium 1640 Invitrogen (Karlsruhe, Germany) 
 
FBS     Invitrogen (Karlsruhe, Germany) 
 
L-alanyl-L-glutamine  Biochrom (Berlin, Germany) 
 
Cell culture flasks   TPP (Trasadingen, Switzerland) 
 
TE     Biochrom (Berlin, Germany) 
 
PBS     - Phosphat buffered saline (Biochrom, Berlin, 
  Germany) 9,55g 
- ad 1L with aqua bidest 
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2.1.4 In vivo experiments 
 
HBG     - Hepes (Biomol, Hamburg, Germany) 2,38g 
     - ad 300mL with aqua bidest 
     - correct with NaOH (VWR International, Darmstadt, 
  Germany) on pH 7,4 
- Glucose-Monohydrat (Merck, Darmstadt, 
  Germany) 2,75g 
- check pH, ad 500mL with aqua bidest 
 
Luciferin    Promega (Mannheim, Germany) 
 
Coelenterazine native  SYNCHEM OHG (Felsberg-Altenburg, Germany) 
 
Isoflurane ®    cp Pharma (Burgdorf, Germany) 
 
Bepanthene ®   Roche (Grenzach-Whylen, Germany) 
 
Syringes    Heiland (Hamburg, Germany) 
 
Needles    Heiland (Hamburg, Germany) 
 
Rimadyl ®    Pfizer (Germany) 
 
Isotonic sodiumchloride  B Braun Melsungen AG (Melsungen, Germany) 
Solution 
 
Monosyn® Easyslide  Heiland (Hamburg, Germany) 
 
G3HDOEI    synthesized in our lab by Dr. Verena Ruß 
([10]) 
Braunol®    B Braun Melsungen AG (Melsungen, Germany) 
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2.1.4.1 Plasmids 
 
pCpG hCMV EF1 Luc  cloned in our lab by Dr. Rudolf Haase ([52]) 
 
pCpG hCMV EF1 extGLuc cloned in our lab by Dr. Rudolf Haase 
 
 
2.1.4.2 Staining 
 
Tissue – Tek Cryomold  Sakura Finetek (Heppenheim, Germany) 
 
Tissue – Tek O.C.T. Compound Sakura Finetek (Heppenheim, Germany) 
 
Tissue – Tek Mega-Casette Sakura Finetek (Heppenheim, Germany) 
 
Bovine Serum Albumin  Sigma Aldrich (Hamburg, Germany) 
 
 Dako Pen    Dako (Glostrup, Denmark) 
 
VECTASHIELD® Mounting Biozol (Eching, Germany) 
Media 
 
Texas Red Dextran 70 000 MW Invitrogen (Karlsruhe, Germany) 
 
FITC Dextran 2 000 000 MW Invitrogen (Karlsruhe, Germany) 
 
CD31 rat anti mouse  BD Pharmingen (Heidelberg, Germany) 
 
Alexa 647 goat anti rat  Invitrogen (Karlsruhe, Germany) 
 
Goat serum    Sigma Aldrich (Hamburg, Germany) 
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2.1.4.3 Laboratory animals 
 
A/JOlaHsd (A/J) mice  Harlan – Winkelmann (Borchen, Germany) 
 
NMRI-nu (nu/nu)   Janvier (Le Genest-St-Isle, France) 
 
 
2.1.4.4 Instruments 
 
IVIS Lumina    Caliper Life Science (Rüsselheim, Germany) 
 
Shaver Philishave C486  Philips (Hamburg, Germany) 
 
Caliper Digi-Met   Peisser (Gammertingen, Germany) 
 
Leica CM 3050 S   Leica Microsystems (Bensheim, Germany) 
 
Leica EG 1150 H   Leica Microsystems (Bensheim, Germany) 
 
 
2.1.5 Software 
 
Living Image 3.0   Caliper Life Science (Rüsselheim, Germany) 
 
GraphPadPrism4   Graph Pad Software (San Diego, U.S.A.) 
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2.2 Methods 
 
2.2.1 Plasmid amplification 
 
From the permanent culture containing pGpG hCMV EF1 extGLuc a pre-culture was 
made in 10mL LB-medium containing Zeocin (50µg/mL) by shaking it 6 hours at 37°C 
and 280 rpm. There after the pre-culture was transferred into six shaking flasks 
containing 500 mL LB-medium and Zeocin (50µg/mL) and shaked over night at 37°C 
and 150rpm. The plasmid was than purified using the EndoFree plasmid kit (giga). 
 
 
2.2.2 Cell culture 
 
Maintenance of cultured cells 
 
All cultured cells were grown at 37 °C in 5% CO2 humidified atmosphere. Neuro2a 
wild type cells, Neuro2a Luc+ and Neuro2a lenti Luc cells were cultured in DMEM 
(1g/L glucose) supplemented with 10% FCS and L-alanyl-L-glutamine (end 
concentration 2mM). LS174T lenti Luc cells were cultured in GIBCO® RPMI Medium 
1640 supplemented with 10% FCS. 
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2.2.3 Animal experiments 
 
Animal experiments were performed according to guidelines of the German law of 
protection of animal life and were approved by the local animal experiments ethical 
committee. Mice were kept under specific pathogen free conditions in isolated 
ventilated cages with 5 animals per cage. Cages were equipped with wood shaving 
litter, a wooden rodent tunnel (except the mice were the tumors were injected into the 
spleen), cellulose bedding and a mouse house. Autoclaved standard breeding chow 
and water were provided ad libitum. A 12 h day/night cycle, 21° celsius room 
temperature and 60% humidity were kept. Mice were allowed to adapt to the housing 
conditions for at least one week before experiments were started. 
 
Characterization of the subcutaneous tumor mouse model with Neuro2a lenti 
Luc cells- kinetic measurements 
 
A/J mice, female, 6 – 10 weeks old were used (n = 5 per group). 
Neuro2a lenti Luc cells were grown in cell culture as described above, being kept in 
antibiotic free medium prior to injection. To harvest the cells they were trypsinated, 
washed three times with PBS and diluted in ice cooled PBS at a concentration of  
106 cells per 150µL. One day prior to tumor cell injection the injection side was 
shaved using a Philishave C486 shaver. 150µL of the cell suspension were injected 
subcutaneously at the right flank of the mice. Tumor size was measured every 
second day by caliper and determined as a*b*c (a = length, b = width, c = height). 
Bioluminescence signal was measured every day by a CCD camera (IVIS Lumina). 
Mice were anaesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) at a flow of 
1L/min. Bepanthene® was put on the eyes to protect them. Thereafter 100µL luciferin 
solution (c = 60mg/mL) were injected intraperitonealy and immediately 
bioluminescence sequence measurement was performed. The sequence was 
measured for 30 minutes with small binning and 5 seconds exposure time. Results 
were evaluated using the Living Image 3.0 software. 
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Characterization and permeability of the intravenous tumor metastasis model 
with Neuro2a Luc+ cells 
 
A/J mice, female, 6 – 10 weeks old were used (n = 9 per group). 
Tumor cells were grown in cell culture as described above, being kept in antibiotic 
free medium prior to injection. To harvest the cells they were trypsinated, washed 
three times with PBS and diluted in ice cooled PBS at a concentration of 106 cells per 
150µL. 150µL of the cell suspension were injected intravenously. The weight of the 
animals was measured every 2 to 3 days. Bioluminescence signal was measured 4 
hours and 24 hours after tumor cell injection and than every 3 to 4 days by a CCD 
camera (IVIS Lumina). For the measurement mice were anaesthetized by inhalation 
of isoflurane in oxygen (2.5% (v/v)) at a flow of 1 L/min. Bepanthene® was put on the 
eyes to protect them. Thereafter 100µL luciferin solution (c = 60mg/mL) was injected 
intraperitonealy and was allowed to distribute 15 minutes prior to bioluminescent 
measurement.  
For the permeability study of the tumor metastases 6 of the 9 mice were injected 10 
minutes before euthanasia with FITC Dextran and Texas Red Dextran and 1 minute 
before euthanasia with Hoechst i.v.. After euthanasia the metastases were 
harvested, imbed into Tissue Tek® and kept at -20° C. After cryosection of the tumor 
metastases using the cryostat a CD31 staining was performed. 
 
CD-31 Staining of the Neuro2a Luc+ tumor metastases for the accessibility 
study 
 
7µm cryosections of the tumor metastases were made and fixed in prechilled MeOH. 
The remaining Tissue Tek was removed the sections were encircled with Dako Pen 
and washed with PBS. The sections were first blocked with 1% BSA in PBS, than 
blocked with 10% goat serum in PBS and incubated 1hour with rat anti mouse CD31. 
After washing they were incubated for 1 hour with Alexa 647 goat anti rat, washed 
and after drying in the dark covered with 1 drop Vectashield Mounting Media. 
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Characterization of the intravenous tumor metastasis model with Neuro2a wild 
type cells 
A/J mice, female, 6 – 10 weeks old were used (n = 10 per group). 
Tumor cells were grown in cell culture as described above, being kept in antibiotic 
free medium prior to injection. To harvest the cells they were trypsinated, washed 
three times with PBS and diluted in ice cooled PBS at a concentration of 106 cells per 
150µL. 150µL of the cell suspension were injected intravenously. The weight of the 
animals was measured every 2 to 3 days. 
 
Characterization of the intravenous tumor metastasis model with Neuro2a lenti 
Luc cells 
 
A/J mice, female, 6 – 10 weeks old were used (n = 6 per group). 
Tumor cells were grown in cell culture as described above, being kept in antibiotic 
free medium prior to injection. To harvest the cells they were trypsinated, washed 
three times with PBS and diluted in ice cooled PBS at a concentration of 106 cells per 
150µL. 150µL of the cell suspension were injected intravenously. The weight of the 
animals was measured every 2 to 3 days. Bioluminescence signal was measured 4 
hours and 24 hours after tumor cell injection and every 3 to 4 days by a CCD camera 
(IVIS Lumina). For the measurement mice were anaesthetized by inhalation of 
isoflurane in oxygen (2.5% (v/v)) at a flow of 1L/min. Bepanthene® was put on the 
eyes to protect them. Thereafter 100 µL luciferin solution (c = 60mg/mL) was injected 
intraperitonealy and was allowed to distribute 15 minutes prior to bioluminescent 
measurement. 
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Establishment of a liver metastases model with Neuro2a lenti Luc cells 
Intrasplenic tumor injection 
 
A/J mice (n = 5) were shaved on the left lateral side of the abdomen behind the 
costal arch one day prior to tumor injection. For tumor injection the mice were 
anaesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) at a flow of 1L/min. 
Bepanthene® was put on the eyes to protect them. Rimadyl® (5mg/kg) was injected 
subcutaneously prior to tumor injection. The mouse was positioned on the right 
lateral side. The shaved skin was first swabbed with ethanol, after it evaporated, the 
skin was swabbed with braunol®. The skin was raised and a vertical cut (ca. 0,5cm) 
throw the skin caudal to the costal arch was made. The muscle-layer and the 
peritoneum were raised and another vertical cut (ca. 0,5cm) was made to open the 
abdominal cavity. The lower part of the spleen was partially displaced out of the 
abdomen and 1x106 Neuro2a lenti Luc cells in 50µl PBS were slowly injected using a 
27G needle. Using a cotton swab, gentle pressure was made on the injection site to 
prevent cell reflux throw the injection channel and bleeding. The spleen was placed 
back to the abdomen. The peritoneum and the muscle were sutured in one layer and 
the skin in another layer using Monosyn® 5/0. The mice were separately put into 
cages with gloves filled with hot water to keep them warm and to recover undisturbed 
from the other mice from surgery. 24 and 48 hours after tumor injection the mice 
were injected subcutaneously 5mg/kg Rimadyl®. 
The mice were weight every two to three days after surgery and the behaviour and 
wound healing was monitored. Bioluminescent imaging was performed as single 
picture imaging at day 4 after tumor injection and as sequence imaging at day seven 
to nine after tumor cell injection. For the bioluminescence imaging the mice were 
anaesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) at a flow of 1 
liter/min. Bepanthene® was put on the eyes to protect them. For the single picture 
imaging the mice were injected 100µL luciferin solution (c = 60mg/mL) 
intraperitonealy and was allowed to distribute 15 minutes prior to bioluminescent 
measurement. For the sequence imaging were the mice placed into the IVIS Lumina 
directly after intraperitoneal luciferin injection.  
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Dual bioluminescence imaging in the intravenous Neuro2a lenti Luc model 
 
A/J mice (n = 7) were injected with 1x106 Neuro2a lenti Luc cells intravenously. The 
animals were imaged 15 minutes after intraperitoneal luciferin injection (300mg/kg) 8 
days after tumor injection to ensure their tumor burden and 14 days after tumor 
injection to localize the tumor metastasis of each animal. There after polyplexes 
containing 2,5mg/kg body weight pCpGhCMV EF1 extGLuc and G3HDOEI (Ruß et 
al) (w/w: 1:1), as a non viral vector, were injected intravenously. 24h and 48h after 
polyplex injection the animals were imaged immediately after intravenous 
colenterazine (4mg/kg) injection. 
 
Dual bioluminescence imaging in the intrasplenic liver metastases model with 
Neuro2a lenti Luc 
 
A/J mice (n = 7) were injected with 1x106 Neuro2a lenti Luc cells intravenously. The 
animals were imaged 15 minutes after intraperitoneal luciferin injection (300mg/kg) 4 
days after tumor injection to ensure their tumor burden. At day 6 after tumor injection 
polyplexes containing 2,5mg/kg body weight pCpGhCMV EF1 extGLuc and 
G3HDOEI (Ruß et al) (w/w: 1:1), as a non viral vector, were injected intravenously. 
24h and 48h after polyplex injection the animals were imaged immediately after 
intravenous colenterazine (4mg/kg) injection. 
 
Gene delivery into Neuro2a wild type tumor metastases in the intravenous 
model 
A/J mice (n = 4) were injected with 1x106 Neuro2a wild type cells intravenously. 
13days after tumor injection polyplexes containing a CpG free plasmid (pCpG hCMV 
EF1 Luc, 2,5mg/kg body weight) encoding for Firefly Luciferase as a reporter gene 
([52]) and G3HDOEI  (w/w: 1:1) as a non viral gene carrier were injected 
intravenously. The animals were imaged 15 minutes after i.p. luciferin injection 24, 48 
and 72 hours after polyplex injection. 
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Gene delivery into Neuro2a wild type tumor metastases in the intrasplenic liver 
metastases model 
 
A/J mice (n = 10) were injected with 1x106 Neuro2a wild type cells into the spleen. At 
day 7 after tumor injection polyplexes containing 2,5mg/kg body weight pCpGhCMV 
EF1 extGLuc and G3HDOEI (Ruß et al) (w/w: 1/1), as a non viral vector, were 
injected intravenously. 24h, 48h and 72h after polyplex injection the animals were 
imaged immediately after intravenous colenterazine (4mg/kg) injection. 
 
 
Establishment of the LS 174T lenti Luc cell line in an intrasplenic liver 
metastasis model 
 
NMRI-nude mice (n = 20) were injected with 7,5x105 LS174T lenti Luc cells into the 
spleen. For tumor injection the mice were anaesthetized by inhalation of isoflurane in 
oxygen (2.5% (v/v)) at a flow of 1 L/min. Bepanthene® was put on the eyes to protect 
them. Rimadyl® (5mg/kg) was injected subcutaneously prior to tumor injection. The 
mouse was positioned on the right lateral side. The skin was first swabbed with 
ethanol, after it evaporated, the skin was swabbed with braunol®. The skin was 
raised and a vertical cut (ca. 0,5cm) throw the skin caudal to the costal arch was 
made. The muscle-layer and the peritoneum were raised and another vertical cut (ca. 
0,5cm) was made to open the abdominal cavity. The lower part of the spleen was 
partially displaced out of the abdomen and the cell suspension was slowly injected 
using a 27G needle. Using a cotton swab, gentle pressure was made on the injection 
site to prevent cell reflux throw the injection channel and bleeding. The spleen was 
placed back to the abdomen. The peritoneum and the muscle were sutured in one 
layer and the skin in another layer using Monosyn® 5/0. The mice were separately 
put into cages with gloves filled with hot water to keep them warm and to recover 
undisturbed from the other mice from surgery. 24 and 48 hours after tumor injection 
the mice were injected subcutaneously 5mg/kg Rimadyl®. 
The mice were weight every two to three days after surgery and the behaviour and 
wound healing was monitored. Bioluminescent imaging was performed as single 
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picture imaging at day 3 after tumor injection and as sequence imaging at day 6, 8 
and 10 after tumor cell injection. For the bioluminescence imaging the mice were 
anaesthetized by inhalation of isoflurane in oxygen (2.5% (v/v)) at a flow of 1 
liter/min. Bepanthene® was put on the eyes to protect them. For the single picture 
imaging the mice were injected 100µL luciferin solution (c = 60mg/mL) 
intraperitonealy and was allowed to distribute 15 minutes prior to bioluminescent 
measurement. For the sequence imaging the mice were placed into the IVIS Lumina 
directly after intraperitoneal luciferin injection.  
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3. Results 
 
3.1. Characterization of Neuro2a lenti Luc cells in a subcutaneous tumor 
mouse model 
 
3.1.1 Tumorigenicity of the Neuro2a lenti Luc cells 
 
To prove the tumorigenicity of the Neuro2a lenti Luc cells, they were inoculated 
subcutaneously into the flank of A/J mice. 
Tumor size was determined by caliper measurement. The transgenic tumors became 
palpable at around day 5 and measurable at around day 7 after tumor inoculation 
(Fig.1). 
Tumors showed an exponential increase in tumor volume (Fig.1) until the mice had to 
be sacrificed due to the tumor size exceeding 15mm in one diameter. 
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Figure 1: Tumor volume development of the Neuro2a lenti Luc cells 
 
1x 106 Neuro2a lenti Luc cells were injected subcutaneously into the flank of A/J mice 
(n = 5). Tumor size was determined every day by caliper measurement starting at 
day 7 after tumor inoculation and calculated as a*b*c*0,4 (length*height*width*0,4).  
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The tumors were harvested and a H&E staining was performed.  As shown in Fig.2 
the tumor is surrounded by a thick capsule. 
 
Figure 2: H&E staining of a subcutaneous Neuro2a lenti Luc tumor 
 
A/J mice were injected with 1x106 Neuro2a lenti Luc cells s.c. At day 11 after tumor 
inoculation the mice were euthanized, the tumors harvested and H&E staining was 
performed. 
 
3.1.2 Firefly Luciferase signal stability in vivo 
 
In the mice used in the experiment above bioluminescence imaging was performed 
every day starting at day 7 after tumor inoculation. The mice were intraperitonealy 
injected with 300mg/kg body weight luciferin. Shortly thereafter the bioluminescent 
signal was measured by BLI. This was performed as time sequence measurement 
(Fig. 3).  
 
 
 
 
 
 
Capsule surrounding 
the Neuro2a lenti 
Luc tumor 
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Figure 3: Sequence measurement of an A/J mouse bearing a s.c. Neuro2a lenti 
Luc tumor 
 
BLI of the mice from the experiment above (Fig. 1) was performed as a time 
sequence measurement. The mice were intraperitonealy injected with 300mg/kg 
body weight luciferin. Shortly thereafter a series consisting of 90 bioluminescence 
images with a delay of 15s from image to image was measured using the IVIS 
Lumina (b)). For the analyses a region of interest was set in the tumor area (c)) and 
the development of the bioluminescent signal, over days and during the 
measurement of each day, could be displayed for each animal (a)).  
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Figure 4: Correlation between mean tumor volume and bioluminescent signal 
in the Neuro2a lenti Luc cells in vivo 
The correlation between the mean bioluminescent signal over days and the mean 
tumor volume over days in the mice from the experiment above was analysed (Fig.1). 
 
A good correlation between Firefly Luciferase expression and tumor volume was 
observed (Fig. 4) 
Since these measurements were performed as sequence measurements (Fig 3), the 
time point of the maximal bioluminescence signal, showing the time point of the 
strongest Firefly Luciferase activity, could be determined (Fig 5). 
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Figure 5: Time point of the maximal bioluminescence signal 
The animals (A/J mice n = 5) were injected with 300mg/kg luciferin i.p. and 
immediately laid into the IVIS Lumina. The bioluminescence measurement of the 
animals shown in figure 1 was performed as sequence measurement consisting of 90 
pictures. The measurement was performed over 5 consecutive days starting at day 7 
after s.c. tumor inoculation. The results are given as box plots. The boxes cover the 
range of 50% of the values above and below the mean. The mark in the box 
indicates the overall mean. 
 
 
The time point of maximal bioluminescence in this tumor model is between 1100 and 
1600 seconds after intraperitoneal luciferin injection (Fig. 5). 
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3.2 Bioluminescence as tool for the characterization of different 
    Neuro2a cell lines in metastatic tumor mouse models 
 
3.2.1 Neuro2a Luc+ cells in the intravenous metastatic tumor model 
 
The tumorigenicity of this cell line has been shown before in the PhD thesis of Dr. 
Gelja Maiwald (LMU). As a first step of the establishment of a syngenic metastatic 
tumor model, the pattern of the tumor metastases (Fig. 7, 14) after intraveneous 
tumor injection were investigated in this experiment. A/J mice were injected with 
Neuro2a Luc+ cells intravenously. The weight (Fig. 6), behaviour and bioluminescent 
signal (Fig. 7) of each animal were monitored. 
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Figure 6: Weight development after intravenous tumor inoculation 
 
A/J mice (n = 9) were injected intravenously with 1x106 Neuro2a Luc+ cells. The 
weight of the animals was determined every 2 to 3 days. The arrow indicates the time 
point where the animals started losing weight. 
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The animals started losing weight at around day 16 (Fig. 6). They started showing 
clinical symptoms (depending on the location of the tumor metastases) like torticollis, 
hind leg pareses, palpable and later visible tumor masses in the abdomen, 
hyperventilation and horrent fur at around day 20 after tumor inoculation. 
In the pathological examination tumor metastases were found in the liver and in the 
lung. Interestingly, they could be found attached to the net in the abdominal cavity 
and, in most of the animals, in the inguinal or axillary area too.  
At the day of tumor inoculation the Neuro2a Luc+ could be visualised by 
bioluminescent imaging at the lung-area (Fig.7). The first day after tumor inoculation 
they could not be visualised anymore and starting at around day 4 the 
bioluminescence could be measured again at the site of the body were the tumor 
metastases started growing. 
 
4h 24h 4d 7d 13d 15d
Figure 7:Development and distribution of Neuro2a Luc+ cells after i.v. injection
A/J mice (n = 9) were injected with 1x106 Neuro2a Luc+ intravenously. 15 minutes after intraperitoneal injection of 
300 mg/kg luciferin bioluminescent pictures were made 4h, 24h, 4d, 7d, 13d and 15d after tumor injection. Here the
bioluminescence pictures of a mouse are shown as a representative example.
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Histological examination (Fig. 8) showed that the tumor is growing expansively and is 
surrounded by a capsule. 
 
 
Figure 8: H&E staining of a Neuro2a Luc+ tumor metastases 
 
A/J (n = 9) mice were injected 1x106 Neuro2a Luc+ cells intravenously. The tumor 
metastases were harvested and H&E staining was performed. Here a metastasis 
found in the abdominal cavity is shown. 
 
 
3.2.2 Accessibility of the Neuro2A Luc+ tumors for macromolecules 
 
After establishing the intravenous tumor model for the Neuro2A Luc+ cells in A/J 
mice, the accessibility of the metastases for fluorescently labelled macromolecules 
with different molecular weight was investigated (Fig. 9). 
A/J mice bearing Neuro2a Luc+ tumor metastases were injected 10 minutes before 
euthanasia with FITC Dextran (MW 2 MDa) and Texas Red Dextran (MW 70.000 
kDa) and 1 minute before euthanasia with Hoechst i.v. Thereafter mice were 
sacrified, metastases were harvested, embedded into Tissue Tek and kept at -20° C. 
After cryosectioning of the tumor metastases a CD31 staining was performed to 
visualize the endothelium. 
Capsule surrounding the Neuro2a 
lenti Luc tumor 
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Figure 9: Accessibility of Neuro2a Luc+ tumor metastases in the intravenous 
tumor model 
 
A/J mice (n = 6) were intravenously injected with 1x106 Neuro2a Luc+ cells. At  
day 14 after tumor inoculation FITC-dextran (green color in the upper left picture) and 
Texas Red-dextran (orange in the lower left picture) were injected 10 minutes before 
euthanasia and Hoechst (blue colored nuclei) 1 minute before euthanasia i.v.. The 
tumor metastases were harvested, cryosections and a CD31 staining (red color in the 
lower right picture) was performed. The white arrow points at the tumor site. The 
yellow dots in the upper right picture are showing the co-localisation of the different 
dyes.  
 
As we show in Fig. 9, Hoechst permeates the tumor tissue. Texas Red Dextran (MW 
70.000 kDa) can be found localized at the endothelium and seems not to permeate 
deeper into the tumor tissue. FITC Dextran (MW 2 MDa) is localized more outside of 
the tumor in the surrounding tissue, but some of it can be found localized also at the 
tumor endothelium. 
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3.2.3 Neuro2a wild type cells: intravenous metastases tumor model 
 
An important issue in gene delivery in vivo is to show the transgene expression over 
time in the same animal. For this purpose a reporter gene, for example luciferase, 
can be used to show success on gene delivery into a tumor. 
For this purpose, an intravenous tumor model with Neuro2a wild type cells was 
established. 
After intravenous inoculation of 1x106 Neuro2a wild type cells, body weight and 
behaviour of each animal was monitored (Fig. 10). 
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Figure 10: Weight development after intravenous injection of Neuro2a wt cells
A/J mice (n = 10) were injected intravenously with 1x106 Neuro2a wt cells. The weight of the animals was determined every 
2 to 3 days. The arrow is indicating the time point where the animals started loosing weight.
 
In this tumor model, animals started losing weight at around day 14 after tumor 
inoculation (Fig. 10) and the same clinical symptoms as in the iv-model with Neuro2a 
Luc+ could be noticed starting at around day 17 after tumor inoculation. 
In the pathological examination the mice show similar tumor distribution pattern than 
the Neuro2a Luc+ cells.  
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Tumor metastases were found in the liver, in the lung, attached to the net in the 
abdominal cavity and, in most of the animals, in the inguinal or axillary area. 
Histological examination showed that the tumor metastases were well vascularised 
(Fig. 11). 
 
 
Figure 11: H&E staining of a Neuro2a wt tumor metastasis in the intravenous 
tumor model 
 
A/J (n = 9) mice were injected with 1x106 Neuro2a wild type cells intravenously. The 
tumor metastases were harvested and H&E staining was performed. 
 
 
3.2.4 Neuro2a lenti Luc cells in the intravenous metastatic tumor model 
 
In a subcutaneous tumor model using Neuro2a Luc+ cells, high day to day variations 
in the bioluminescent imaging signal were found (Dr. Maiwald, PhD thesis). To 
investigate if Neuro2a cells marked with a lentiviral Luc encoding vector give more 
stable BLI signals, A/J mice have been injected intravenously with Neuro2a lenti Luc 
cells. The weight, behaviour and bioluminescent signal of each animal were 
monitored (Fig. 12). 
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Figure 12: Weight development after intravenous tumor inoculation 
A/J mice (n = 6) were injected intravenously with 1x106 Neuro2a lenti Luc cells. The 
weight of the animals was determined every 2 to 3 days. The arrow indicates the time 
point where the animals started loosing weight. 
 
The weight, behaviour and bioluminescent signal of each animal were monitored. 
The animals started losing weight at around day 16 after tumor inoculation (Fig. 12). 
They started showing clinical symptoms (depending on the location of the tumor 
metastases) like torticollis, hind leg pareses, palpable and later visible tumor masses 
in the abdomen, hyperventilation and horrent fur at around day 20 after tumor 
inoculation. 
Histological examination showed that the tumor is growing expansively, is well 
vascularised and also surrounded by a capsule (Fig.13). The Neuro2a lenti Luc cells 
showed the same spreading pattern as the Neuro2a Luc+ cells. Large tumor nodules 
could be found within the liver (Fig. 14) and the histological examination showed that 
they are growing reflationary (Fig.13). 
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Figure 13: H&E staining of a Neuro2a lenti Luc tumor metastasis in the 
intravenous tumor model 
 
A/J (n = 5) mice were injected with 1x106 Neuro2a lenti Luc cells intravenously. The 
tumor metastases were harvested 24 days after tumor inoculation and H&E staining 
was performed. 
 
 
 
 
Figure 14: Liver metastases in the intravenous tumor model with Neuro2a lenti 
Luc cells 
 
Liver metastases of an A/J mouse after euthanasia 24 days after tumor inoculation. 
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3.2.5 Neuro2a lenti Luc cells in a liver metastases model 
 
A so far not solved issue in cancer therapy is the successful treatment of metastases. 
In the previous tumor models, the tumor cells were injected directly into the blood 
stream, so they did not need to change their properties to disseminate from a primary 
tumor ([53]). To establish a tumor model, where the tumor cells can infiltrate the liver, 
Neuro2a lenti Luc cells were inoculated into the spleen, similar as it has been 
described for colon carcinoma ([49], [50], [51]). 
The weights (Fig.15), behaviour and bioluminescent signal (Fig. 16) of animals were 
monitored. 
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Figure 15: Weight development after intrasplenic tumor inoculation 
 
A/J mice (n = 5) were injected with1x106 Neuro2a lenti Luc cells into the spleen. The 
weight of the individual animals was determined every 2 to 3 days. 
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The animals started loosing weight at around day 7 after tumor inoculation (Fig. 15).  
At around day 9 after tumor inoculation masses in the upper part of the abdominal 
cavity became visible. At around day 10 after tumor inoculation we could observe the 
animals to arch the back, to walk more with caution and unwillingly stretching the 
body to the cratch. The primary tumor in the spleen area could be visualized by 
bioluminescent imaging at day 4 after tumor inoculation. Metastases from the primary 
tumor into the liver can be most of the time measured by bioluminescent imaging at 
day 4 after tumor inoculation too (Fig. 16). 
4d 7d 9d
 
Figure 16: Bioluminescence over the days 
 
A/J mice were injected with 1x106 Neuro2a lenti Luc cells i.s. 15 minutes after i.p. 
injection of 300mg/kg luciferin bioluminescence was measured at day 4 after tumor 
inoculation. Starting at day 7 after tumor inoculation the measurement was performed 
as sequence measurement. 
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Figure 17: Time point of maximal bioluminescence in the intrasplenic liver 
metastases tumor model 
 
Tumor bearing A/J mice (n = 5) were injected with 300mg/kg luciferin i.p. and 
immediately laid into the IVIS Lumina. The bioluminescence measurement of the 
animals was performed as sequence measurement consisting of 90 pictures. The 
measurement was performed over 3 consecutive days starting at day 7 after tumor 
inoculation. The results are given as box plots. The boxes cover the range of 50% of 
the values above and below the mean. The mark in the box indicates the overall 
mean. 
 
The time point of maximal bioluminescence in this tumor model was between 750 to 
1150 seconds after intra peritoneal luciferin injection indicating that the best time 
point for the measurement of the Firefly Luciferase expression after luciferase knock 
down mediated by a non viral vector lies in this interval (Fig. 17) 
The Bioluminescent Imaging signal was increasing over time between day 7 and 9 
after tumor inoculation (Fig. 18). 
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Figure 18: Bioluminescence over days in the intrasplenic liver metastases 
tumor model with Neuro2a lenti Luc  
 
Tumor bearing A/J mice (n = 5) were injected with 300mg/kg luciferin i.p. and 
immediately laid into the IVIS Lumina. The bioluminescence measurement of the 
animals was performed as sequence measurement consisting of 90 pictures (mean 
value given in the graph). The measurement was performed over 3 consecutive days 
starting at day 7 after tumor inoculation. 
 
The pathological examination of the animals showed a primary tumor on the injection 
site in the spleen and a liver which was full with metastases (Fig. 19). No metastases 
were found in the abdominal cavity or lymph nodes. Small tumor nodules all over the 
liver were found in comparison to the larger nodules found in the i.v. model (Fig. 14). 
There are differences also in the histology of the liver metastases of both models. In 
the intrasplenic injected one are the tumor nodules not growing expansively anymore, 
they are disseminated all over the liver tissue (Fig. 20).  
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Figure 19: Liver metastases in the intrasplenic liver metastasis tumor model 
with Neuro2a lenti Luc cells 
 
Liver metastases of an A/J mouse after euthanasia 10 days after intrasplenic 
injection of Neuro2a lenti Luc cells. 
 
Figure 20: H&E staining of a Neuro2a lenti Luc tumor metastases in the 
intravenous and intrasplenic liver metastases tumor model 
 
Comparison of a liver bearing intravenously injected Neuro2a lenti Luc metastases 
(picture on the left side) and intrasplenic injected N2a lenti Luc metastases (picture 
on the right side).  
 
Liver metastases 
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3.3. Dual bioluminescence imaging as tool to monitor the success of non viral 
gene delivery in metastatic tumor models 
 
3.3.1 Membrane bound Gaussia Luciferase as a novel reporter gene for gene 
delivery 
 
A problem occurring often in metastastic tumor models with wild type tumor cells is 
that there is no possibility to distinguish between animals which are tumor bearing 
and the ones which do not bear a tumor in the early stage of disease. With the 
Neuro2A lenti Luc cell line we have the possibility to do experiments only with 
animals bearing tumor metastases. To determine which tumor metastases have been 
transfected with our non viral vector after i.v. injection, we have chosen a highly 
effective plasmid encoding for a membrane bound version of Gaussia Luciferase 
(extGLuc), optimized for in vivo expression, as reporter gene (Fig. 21).  
 
pCPG-hCMVEF1-
exGLUC
3763 bp
R6K Ori + ZEOCIN Res. (pCPG-MCS) 3043...3763
SV40 late polyA 2005...2196
EF1-Promoter 758...975
SI 126 982...1151
hCMV enhancer 429...751
IFN-MAR 2235...3034
ß-Glo MAR 9...415
extGLUC 1194...1994
 
Figure 21: Plasmid card of the CpG-free plasmid encoding for a membrane 
bound version of Gaussia Luciferase used in the experiments 
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3.3.2 Dual bioluminescence imaging in the intravenous Neuro2a lenti Luc 
model 
 
To monitor the ability to transfect disseminated metastases after systemic vector 
application, A/J mice were inoculated with Neuro2a lenti Luc cells intravenously. The 
animals were imaged 15 minutes after intraperitoneal luciferin injection to localize the 
tumor metastases at day 8 and 14 after tumor inoculation (Fig. 22). Thereafter 
polyplexes containing pCpGhCMV EF1 extGLuc and G3HDOEI ([10]), as a non viral 
vector, were injected intravenously. At 24h and 48h after polyplex injection the 
animals were imaged immediately after intravenous coelenterazine injection (Fig. 22). 
Firefly Gaussia
24h
48h
   
Figure 22: Dual bioluminescence imaging in the intravenous Neuro2a lenti Luc 
model 
 
A/J mice (n = 7) were injected with 1x106 Neuro2a lenti Luc cells intravenously. The 
mice were imaged 15 minutes after intraperitoneal luciferin (300mg/kg) injection  
8 days after tumor inoculation to ensure their tumor burden and 14 days after tumor 
inoculation to localize the tumor metastases of each animal. 14 days after tumor 
inoculation polyplexes containing pCpGhCMV EF1 extGLuc and G3HDOEI ([10]), as 
a non viral vector, were injected intravenously. 24h and 48h after polyplex injection 
the animals were imaged immediately after intravenous coelenterazine (4mg/kg) 
injection. 
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In all animals, we observed a more or less strong reporter gene expression through 
bioluminescent imaging indicating that the tumor metastases are well accessible for 
our non viral gene delivery system. 
 
3.3.3 Dual bioluminescence imaging in the intrasplenic Neuro2a liver 
metastases model 
 
To prove the ability of non viral gene delivery in this model, we injected A/J mice  
(n = 6) 1x106 Neuro2a lenti Luc cells into the spleen. The animals were imaged 15 
minutes after intraperitoneal luciferin injection at day 4 after tumor inoculation to 
monitor tumor burden (Fig. 23). At day 6 after tumor inoculation they have been 
injected polyplexes containing pCpGhCMV EF1 extGLuc and G3HDOEI ([10]), as a 
non viral vector, intravenously. 24h and 48h after polyplex injection the animals were 
imaged immediately after intravenous coelenterazine injection (Fig. 23).  
Firefly Gaussia
24h
48h
 
Figure 23: Dual bioluminescence imaging in the intrasplenic liver metastases 
model 
 
A/J mice (n = 6) were injected with 1x106 Neuro2a lenti Luc cells into the spleen. The 
mice were imaged 15 minutes after intraperitoneal luciferin (300mg/kg) injection 
 4 days after tumor inoculation to ensure their tumor burden. 6 days after tumor 
inoculation polyplexes containing pCpGhCMV EF1 extGLuc and G3HDOEI ([10]) as 
a non viral vector, were injected intravenously. 24h and 48h after polyplex injection 
the animals were imaged immediately after intravenous coelenterazine (4mg/kg) 
injection. 
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In all animals, we observed a more or less strong reporter gene expression through 
bioluminescent imaging indicating that the tumor metastases are well reachable for 
non viral gene delivery.  
 
3.4 Non viral gene delivery into wild type Neuro2a tumor metastases in vivo 
 
3.4.1 Gene delivery into wild type tumor metastases in the intravenous model 
 
To prove the ability to transfect the Neuro2a wild type tumor metastases in the 
intravenous model, tumor bearing A/J mice were injected with polyplexes containing 
a CpG free plasmid (pCpG hCMV EF1 Luc) encoding for Firefly Luciferase as a 
reporter gene ([52]) and G3HDOEI as a non viral gene carrier 13 days after 
intravenous tumor inoculation. The animals were imaged 15 minutes after i.p. 
luciferin injection. Here the bioluminescent pictures of a mouse are shown as a 
representative example (Fig. 24). 
24h 48h 72h
 
Figure 24: Gene delivery into wild type tumor metastases in the intravenous 
model 
A/J mice (n = 4) were injected with 1x106 Neuro2a wild type cells intravenously. 13 
days after tumor inoculation polyplexes containing a CpG free plasmid (pCpG hCMV 
EF1 Luc) encoding for Firefly Luciferase as a reporter gene ([52]) and G3HDOEI as a 
non viral gene carrier were injected intravenously. The animals were imaged 15 
minutes after i.p. luciferin injection (300mg/kg) 24, 48 and 72 hours after polyplex 
injection. 
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3.4.2 Gene delivery into wild type Neuro2a tumor metastases in the intrasplenic 
liver metastases model 
 
To prove the ability to transfect the Neuro2a wild type tumor metastases in the 
intrasplenic liver metastases model, tumor bearing A/J mice (n = 10) were injected 
with polyplexes containing a CpG free plasmid encoding for the membrane bound 
Gaussia Luciferase as a reporter gene and G3HDOEI as a non viral gene carrier       
7 days after tumor cell injection. Here the bioluminescent pictures of a mouse are 
shown as a representative example (Fig. 25). 
 
Before 24h 48h
 
Figure 25: Gene delivery into wild type tumor metastases in the intrasplenic 
liver metastases model 
 
A/J mice (n = 10) were injected with 1x106 Neuro2a wild type cells into the spleen. At 
day 7 after tumor inoculation polyplexes containing a CpG free plasmid encoding for 
the membrane bound Gaussia Luciferase as a reporter gene and G3HDOEI as a non 
viral gene carrier were injected intravenously. 24, 48 and 72 hours after polyplex 
injection the mice were imaged immediately after coelenterazine injection. 
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We have determined the background signal in the animals from the experiment 
above. Six days after tumor inoculation luciferin was injected intraperitonealy and  
15 minutes later bioluminescence imaging was performed (Fig. 26 A). Seven days 
after tumor inoculation coelenterazine was injected intravenously and 
bioluminescence imaging was performed immediately (Fig. 26 A). Thereafter the 
animal received polyplexes containing pCpGhCMVEF1extGLuc and G3HDOEI 
intravenously. One day after polyplex injection the animals were imaged immediately 
after intravenous coelenterazine injection and 6 hours later after intraperitoneal 
injection of luciferin (Fig 26 B, left part of the graph). Three days after polyplex 
injection another bioluminescence imaging was performed immediately after 
intravenous coelenterazine injection (Fig. 26 B, right part of the graph). 
Transgene delivery into Neuro2a wt metastases in the
intrasplenic liver tumor metastases model
A
B
 
´ 
Figure 26: Transgene delivery into Neuro2a wild type tumor metastases in the intrasplenic liver 
metastases model 
 
A – Neuro2a wt liver metastases bearing A/J mice (n=10). BLI signal after intraperitoneal injection of 
300mg/kg luciferin at day 6 and after intravenous injection of 4mg/kg coelenterazine at day 7 after 
tumor inoculation. 
B – BLI signal of the mice from A at day one and three after intravenous injection of polyplexes 
containing pCpGhCMVEF1extGLuc and G3HDOEI. On the left the BLI signals after intraperitoneal 
resp. intravenous injection of 300mg/kg luciferin resp. 4mg/kg coelenterazine at day 1 are schown. On 
the right the BLI signal after intravenous injection of 4mg/kg coelenterazine is shown. 
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3.5 Establishment of a metastatic xenograft for gene delivery 
 
3.5.1 Establishment of the LS 174t lenti Luc cell line in an intrasplenic liver 
metastases model 
 
It is known for colorectal cancer that hepatic metastasis is the most common cause of 
death in these patients ([49]). For this reason it was aimed to establish a xenogeneic 
liver metastasis model using the LS174T in our lab, where it is from the literature 
known that liver metastasis can be achieved by injecting the tumor cells into the 
spleen ([49], [50], [51]). 
NMRI-nude mice were injected LS174T lenti Luc cells into the spleen. The animals 
were monitored concerning weight (Fig. 27), behaviour and bioluminescent signal 
(Fig. 28, 29). 
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Figure 27: Weight development after intrasplenic tumor inoculation 
 
NMRI–nude mice (n = 20) were injected with 7,5x105 LS174T lenti Luc cells into the 
spleen. The weight was determined every 2 to 3 days after tumor inoculation. 
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In this tumor model the animals start losing weight at around day 8 after tumor 
inoculation (Fig. 27). Approximately at the same time tumor masses in the abdominal 
cavity become palpable. At around day 9 after tumor inoculation the mice had shown 
an increased girth in the upper part of the abdominal cavity. At around day 10 after 
tumor inoculation we could observe the animals to arch the back, to walk more with 
caution and unwillingly stretching the body to the cratch.  
There is an increase of the bioluminescence signal between day 3 and day 10 after 
tumor inoculation, indicating progressive growth of the viable tumor mass (Fig. 28). 
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Figure 28: Bioluminescence development 
 
NMRI–nude mice (n = 20) were injected with 7,5x105 LS174T lenti Luc cells into the 
spleen. 15 minutes after i.p. injection of 300mg/kg luciferin bioluminescence was 
measured at day 3 after tumor inoculation. Starting at day 6 after tumor inoculation 
the measurement was performed as sequence measurement. 
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Figure 29: Bioluminescence development 
 
NMRI – nude mice (n = 20) were injected with 7,5x105 LS174T lenti Luc cells into the 
spleen. 15 minutes after i.p. injection of 300mg/kg luciferin bioluminescence was 
measured at day 3 after tumor inoculation. Starting at day 6 after tumor inoculation 
the measurement was performed as sequence measurement. Here the pictures of an 
example mouse are shown at day 3, 6, 8 and 10 after tumor inoculation (from the left 
to the right). 
 
LS174T tumor metastases can be visualized at day 3 after tumor inoculation in all 
animals (Fig. 29).We can find only a bioluminescent signal within the spleen and liver 
area. Starting at day six after tumor inoculation, the bioluminescent measurements 
were performed as sequence measurement so it was possible to determine the time 
point of maximal bioluminescence for this tumor model (Fig. 30). 
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Figure 30: Time point of maximal bioluminescence in the intrasplenic liver 
metastases model with LS174T lenti Luc 
 
NMRI–nude mice (n = 20) were injected with 7,5x105 LS174T lenti Luc cells into the 
spleen. At day 6, 8 and 10 after tumor inoculation bioluminescence imaging was 
performed immediately after intraperitoneal injection of 300mg/kg luciferin. The 
bioluminescence imaging was performed as sequence measurement. The results are 
given as box plots. The boxes cover the range of 50% of the values above and below 
the mean. The mark in the box indicates the overall mean 
. 
The time point of maximal bioluminescence in this tumor model was found at around 
1100 seconds.  
The pathological examination showed that all of the animals were tumor bearing. In 
all animals a primary tumor in the spleen was found which appeared harder in the 
texture than the metastases found in the liver. The liver metastases (Fig. 31) were 
macroscopically different than the liver metastases found in the intrasplenic Neuro2a 
lenti Luc liver metastases model (Fig. 19). 
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Figure 31: Liver metastases in the intrasplenic liver metastases tumor model 
with LS174T lenti Luc 
 
Photograph of a mouse bearing LS174T lenti Luc liver metastases 12 days after 
intrasplenic tumor inoculation. The normal liver tissue is marked with the red arrow, 
the metastases with the black one. 
 
The histological examination showed that the metastases in this model are not 
growing infiltrating but expansively (Fig. 32). They are surrounded by a thin capsule 
and seem to form also cyst-like structures. In the H&E staining we can nicely see 
central necrosis in the metastases surrounded by well differentiated vital tumor cell 
layers. 
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C D
 
 
Figure 32: Comparison of normal liver tissue and liver tissue bearing LS174T 
lenti Luc metastases. 
 
(A) Normal liver tissue.  
(B) LS174T lenti Luc metastases with central necrosis (red arrow) and a thin capsule 
(black arrow)  
(C) Micro-metastases of LS174T lenti Luc near a blood vessel 
(D) Cyst-like structures in LS174T lenti Luc metastases 
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4. Discussion 
 
4.1 Intravenous metastases model 
 
The aim of this work was to establish liver tumor metastases models in mice 
(syngeneic as well as xenogeneic), using luciferase as reporter gene which could be 
used in further experiments for the development of novel defined and fully synthetic 
non viral gene (or siRNA) vectors for the delivery into tumor tissue allowing cancer 
treatment. 
The Neuro 2aLuc + cell line had been established in our lab in the PhD thesis of Dr. 
Gelja Maiwald (LMU). Based on the publication of Amirkhosravi et al ([48]) we 
decided to establish the intravenous liver metastases tumor model using the Neuro2a 
Luc+ cells because of the possibility to follow the spreading pattern and metastases 
development in real time. Using these cells allowed us to visualize tumor burden in 
an early stage of the metastases development (at day four after intravenous tumor 
cell injection) opening the possibility of better sectioning of the animals into treatment 
groups. If a treatment over a longer time in a fast growing tumor metastases model is 
aimed at without using this early stage bioluminescent imaging, one had to do the 
distribution of animals into the different treatment groups complete blind; large group 
to group variations in the composition of the groups may occur which can lead to 
difficult analyses of the experiment (e.g. one group with all animals tumor bearing 
and another with just a few tumor bearing animals). The animals injected 
intravenously Neuro2a Luc+ cells developed extensively metastases, contrary to the 
data publicated by Amirkhosravi et al ([48]), not only in the liver (not in every tumor 
inoculated animal) and lung, but also in the axillary/inguinal area, attached to the net 
or small intestine. Although the spreading pattern differed from animal to animal, all 
mice that were tumor inoculated also developed more or less extensive tumor 
metastases.  
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Croce et al ([25]) had shown evidence that IL-21-secreting NB cells are effective as 
therapeutic vaccine in mice bearing metastatic NB, through a specific CTL response 
involving surviving as antigen, and suggest a potential interest for IL-21 in NB 
immuno-gene therapy. The mean tumor free survival time in the non treated animals 
was 22 days, similar to the founding we had using the Neuro2a Luc+ cells, indicating 
that the modification of the Neuro2a wild type cells into the Neuro2a Luc+ cells had 
not changed their spreading patter and metastases development potential in vivo. To 
prove this we inoculated Neuro2a wild type cells intravenously. We could confirm in 
our experiment that the mice had shown the same mean survival time than the once 
inoculated with Neuro2a Luc+ cells and had shown in the pathological examination 
after the sacrifice the same spreading pattern. 
We also investigated the accessibility of the Neuro2a Luc+ metastases in the 
intravenous metastases model for macromolecules using 70.000 kDa Texas-Red 
Dextran and 2 MDa FITC-Dextran applied intravenously 10 minutes before the tumor 
bearing mice were sacrificed. After cryosectioning and CD31 staining of the tumor 
metastases, to visualize the endothelium, we found the Texas-Red Dextran localized 
at the endothelium. Although the FITC-Dextran could be also found at the 
endothelium, it was more localized in the tumor surrounding tissue.  
 
 
4.2 Establishment of the Neuro2a lenti Luc cell line 
 
Andrew Fire and Craig Mello won 2006 consequently the Nobel Prize for their work 
on RNA interference in Caenorhabditis elegans which was published in the year 
1998 ([54]). Delivering small interfering RNA (siRNA) to tumors is the major technical 
hurdle that prevents the advancement of siRNA-based cancer therapy. Bartlett et al. 
for the first time proved successful siRNA delivery to tumor tissue by directly targeting 
luciferase ([55],[56]). One of the difficulties associated with the development of 
clinically relevant delivery systems is the lack of reliable tools for monitoring siRNA 
delivery to tumors in vivo. Lin et al ([57]) described in his publication a positive read 
out system for siRNA delivery by using tet repressor based inducible expression 
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 systems, where potent siRNA against TetR, when introduced into cells, serves as an 
inducing agent by knocking down the TetR protein, thus allowing up-regulation of the 
reporter. For using a luciferase based negative read out system for the detection of 
siRNA mediated knock down, it is crucial that the bioluminescence imaging signal in 
the reporter gene expressing tumor cells stays stable. This would allow traceability of 
the specific siRNA mediated luciferase knock down below normal bioluminescence 
imaging signal deviations.  
Dr. Maiwald had found in her PhD thesis in a subcutaneous tumor model using 
Neuro2a Luc+ cells inoculated into the flank of fully immunocompetent A/J mice, high 
day to day variations in the bioluminescent signal. We developed the Neuro2a lenti 
Luc tumor cell line via lentiviral transduction (Arzu Cengizeroglu, LMU), to investigate 
if Neuro2a cells marked with a lentiviral Firefly Luciferase encoding vector are more 
stable in the bioluminescence imaging signal. The tumorigenicity of the cell line had 
been proven by establishing this tumor cell line in a subcutaneous model in fully 
immunocompetent A/J mice. The experiment had shown an exponential increase in 
tumor volume, which also correlated well with the mean bioluminescence imaging 
signal over days (r2 = 0,9342). The bioluminescence imaging was performed as a 
sequence measurement meaning that the mice were put into anesthesia (using a 
chamber floated with isofluran and oxygen) and immediately after luciferin injection 
the bioluminescence measurement was performed capturing 90 pictures with a delay 
of 30 seconds between the pictures. Performing the measurement this way, we had 
the possibility to follow also the time kinetics of light production in the Firefly 
Luciferase expressing tumor cells. We have found that in the subcutaneous tumor 
model the time point of the strongest bioluminescent imaging signal was between 
1100 and 1600 seconds. While evaluating the data of this experiment we have found 
no day to day BLI signal deviations, proving that the lentiviral transduced cells are 
stable in the BLI signal.  
 
 
 
 
57 
 
Chapter 4: Discussion 
 
 
4.3 Metastatic tumor models using Neuro2a lenti Luc 
 
Following up the experiments done with the Neuro2a Luc+ and wild type cells, we 
compared the Neuro2a lenti Luc cells in the intravenous metastases model and 
found the same pattern in metastases development. To establish a tumor model 
where the tumor cells can infiltrate the liver, Neuro2a lenti Luc cells were inoculated 
into the spleen, similar as it has been described for colon carcinoma ([49], [50], [51]). 
Similar as in the intravenous model it was possible to visualize the tumor cells (the 
primary tumor as well as the liver metastases) already at day 4 after tumor 
inoculation. Different than in the intravenous model the mice started losing weight 
much earlier (at about day 7) and masses in the upper abdomen became first visible, 
then palpable and shortly thereafter had to be euthanized due to animal welfare (at 
around day 10). As we had observed that the tumor metastases are growing much 
faster in this tumor model we decided to monitor the time kinetics of light production 
in the Firefly Luciferase expressing tumor cells the same way we already did for the 
subcutaneous tumors. We observed that the time point of maximal BLI signal in this 
tumor model was between 750 to 1150 seconds, so about 500 seconds earlier than 
in the subcutaneous model, which could be due to the intraperitoneal luciferin 
application allowing it to earlier reach the tumor metastases in the abdominal cavity. 
The BLI signals were stronger than in the subcutaneous model, which could be 
associated with a higher proliferation rate and there for higher amount of tumor cells 
in the metastases with available luciferase, but this aspect needs to be further 
evaluated. Comparing the histology in these two tumor models, we have found on the 
one hand the subcutaneous tumor surrounded by a capsule growing expansively with 
a central necrosis, and on the other hand the tumor metastases in the intrasplenic 
model, infiltrating the liver tissue where it is not possible to find a border between 
single metastases (like it is possible in the intravenous model). The relationship 
between these different growth properties in the tumor models, their BLI signal 
intensity and their different time kinetics need to be further evaluated. 
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4.4 Dual Bioluminescence Imaging 
 
Shah et al ([58]) decribes a way to monitor both, gene delivery and efficacy of Tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in 
tumors in vivo in real time by dual enzyme substrate (Rluc/Fluc) imaging in a 
subcutaneous xenograft model using human glioma cells (Gli36) stably transfected 
with Firefly Luciferase (Gli36fluc+) and a HSV amplicon vector bearing the genes for 
TRAIL and Rluc injected directly into Gli36fluc+. Tannous et al is also discussing the 
possibility to use a system based on two luciferases ([47]) but using Gaussia 
Luciferase instead of Renilla Luciferase. Serganova et al ([59]) could show in a 
multimodality imaging approach, that exGluc BLI demonstrates a significantly higher 
sensitivity than MicroPET imaging, thereby allowing detection of TGFß activation 
much earlier and in more sites of metastatic growth in the mouse. As we had 
established tumor metastases models with Neuro2a lenti Luc cells stably expressing 
Firefly Luciferase, we decided to use a novel plasmid encoding for the membrane-
bound version of Gaussia Luciferase ([60]) for the monitoring of the gene delivery 
efficacy of our non viral gene delivery system via dual bioluminescent imaging in real 
time. In both tumor models we were able to localize the Firefly Luciferase labeled 
tumor metastases 10 minutes after intraperitoneal luciferin injection and Gaussia 
Luciferase transfected tumor metastases immediately after intravenous injection of 
coelenterazine. Comparing the BLI signals of Gaussia Luciferase from these 
experiments, we found stronger BLI signals in the intrasplenic liver metastases 
model, indicating that the metastases developed by infiltrating the liver are easier to 
transfect with our non viral vector than the ones derived by intravenous injection. 
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4.5 Non viral gene delivery into wild type tumor metastases 
 
In terms of the development of non viral vectors for gene delivery it is use full to have 
a metastatic tumor model, where it is possible to compare different synthetic vectors 
due to their ability to deliver a gene functional into a tumor cell. There are few 
approaches described in the literature for the use of plasmid DNA delivered into a 
tumor in the literature. One approach is delivering a plasmid encoding for Diphteria 
toxin into cancer cells leading to tumor growth inhibition ([61,62]). Another approach 
is to use a plasmid encoding for TNFα leading to a tumor necrosis ([62]). To prove 
the functionality of our non viral vector system we have decided to use our novel 
plasmids, encoding either for Firefly Luciferase or for the membrane bound Gaussia 
Luciferase, as reporter for a functional gene delivery.  We could show that there are 
no significant differences between the spreading patterns and growth characteristics 
between the Neuro2a wild type cells and the lentiviral transduced Neuro2a lenti Luc 
cells. For this reason we decided to use Neuro2a wild type metastases in this 
approach. To ensure measurement of the bioluminescent imaging signal from our 
gene delivery into the metastases and not the unspecific background signals, we 
detected the background signal of each substrate (luciferin and coelenterazine) in the 
tumor bearing mice before the injection of the reporter gene complexed with the non 
viral vector (G3HDOEI).By BLI 24, 48 and 72 hours after polyplex injection, we found 
a BLI signal which was clearly stronger than the background signal, indicating that 
this method is suitable for the development of non viral delivery systems. 
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4.6 Establishment of a metastatic xenograft model for non viral 
gene delivery 
 
It is known for colorectal cancer that hepatic metastasis is the most common cause of 
death in these patients ([49]). Because the LS174T cell line is a human colon 
carcinoma cell line, the cells are expressing human target molecules opening the 
possibility of targeted gene delivery. For this reason it was aimed to establish in our 
lab a xenogeneic liver metastasis model using the LS174T, where it is from the 
literature known that liver metastasis can be achieved by injecting the tumor cells into 
the spleen ([49], [50], [51]). The aim was to establish this model as negative read out 
model for, siRNA mediated knock down via non viral delivery. There are different 
informations regarding the cell amount to be injected into the spleen and the 
metastases growth kinetics in the literature ([50], [49], [63], [51]). We used 1 milion 
LS174T cells stable expressing Firefly Luciferase injected into the spleen. There was 
an increase of the BLI signal between day 3 and 10 indicating a progressive growth 
of the viable tumor mass and proving the stability of the BLI signal making this model 
suitable for non viral gene delivery vector development. Similar to the finding we had 
made for the syngeneic Neuro2a lenti Luc metastases model, the tumor metastases 
could be visualized via BLI about day 4 after tumor inoculation. Like in the Neuro2a 
lenti Luc intrasplenic tumor model the tumor metastases were found at the primary 
injection site and as metastases in the liver. We found differences in the growth 
characteristics of the tumor metastases in the liver (cyst-like structures with a thin 
capsule and necrotic center), but also in the kinetics of light production of the Firefly 
Luciferase after luciferin injection. The mean maximal BLI signal was found to be at 
around 1100 seconds, which could be due to the different proliferation of the tumor 
cells, their growth characteristics and could be specific for this cell line and should be 
further evaluated as well as the accessibility of the tumor metastases for non viral 
gene delivery. 
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5. Summary 
 
Cancer metastases are the main causes of mortality in humans. New treatment 
approaches like gene therapy did arise during the last decade. Gene therapy using 
plasmid DNA is already in clinical trials. A novel approach is the use of small 
interfering RNA (siRNA) acting on translational level without the introduction of genes 
into the genome. Due to the fast clearance and degradation of siRNA, when injected 
naked into the bloodstream, delivery systems have to be developed. For this purpose 
feasible tumor models are needed. We established two different metastatic 
syngeneic tumor models based on neuroblastoma Neuro2a lenti Luc, Neuro2a Luc+ 
and Neuro2a wild type cells in syngeneic A/J mice. Systemic metastases were 
established by intravenous injection of tumor cells, liver metastases were generated 
by spleen injection.  
The tumor models stably expressing Firefly luciferase can be used for tumor 
metastases trafficking (in the intravenous model) as well as for knock down 
experiments with siRNA, or plasmid delivery to the metastases by in vivo luciferase 
imaging.  
The wild type tumor models can be used for the evaluation of new fully synthetic 
nonviral carrier systems using different luciferases as reporter gene to show 
successful delivery of the functional construct into the target cells. For plasmid DNA 
delivery we applied a biodegradable polypropylenimine dendrimer generation 3 
modified with branched oligoethylenimine 800Da (G3-HD-OEI).  
In the current thesis we could show that novel plasmids encoding for Firefly or 
Gaussia luciferase are feasible for the purpose of live animal in vivo imaging. The big 
advantage of these syngeneic models is the intact immune system of the mice so it is 
possible to investigate the interactions between the construct and the immune 
system. The big advantage of these models is the possibility to study the effects in a 
syngeneic mouse model with a functional immune system. 
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In addition the established technology was also applied for setting up a xenograft 
model for liver metastases of colon carcinoma using the human LS174T cell line in 
luciferase-expressing form.  
In conclusion both syngeneic and xenograft models of experimental liver metastases 
and/or systemic metastases were established and used in luciferase imaging 
experiments to monitor in vivo tumor growth, distribution, and synthetic non viral gene 
transfer.  
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6. Zusammenfassung 
 
Laut dem Statistischen Bundesamt starb im Jahr 2009 jeder 4. Mensch in 
Deutschland an einer Krebserkrankung. Tumorentwicklung und die Bildung von 
Metastasen spielen deshalb in der pharmazeutischen Forschung eine besondere 
Rolle. Insbesondere die Gentherapie sowie die Therapie mit Hilfe von RNA-
Interferenz stehen hierbei im Fokus.  
Mit Hilfe von RNA-Interferenz ist es möglich auf der Übersetzungsebene der RNA 
einzugreifen ohne das Genom selber zu modifizieren. Ungeschützt in den Blutstrom 
appliziert, wird siRNA sehr schnell ausgeschieden und abgebaut, aus diesem Grund 
ist es wichtig Transportsysteme zu entwickeln, welche den erfolgreichen siRNA-
/Gentransfer in die Tumorzelle ermöglichen.  
Um diese Transportsysteme auf ihre Funktionalität in vivo überprüfen zu können 
wurden in dieser Arbeit zwei verschiedene syngene Tumormodelle, basierend auf 
den Neuroblastomzelllinien Neuro2a lenti Luc, Neuro2a Luc+ und Neuro2a Wildtyp, 
in syngenen A/J Mäusen entwickelt. Systemische Metastasen wurden entweder 
durch intravenöse Injektion oder durch Injektion in die Milz etabliert. 
 
Krebsmodelle, welche stabil Firefly Luziferase exprimieren, können sowohl für das 
Lokalisieren von den Krebsmetastasen im Körper, als auch für Knockdown-
Experimente mit siRNA genutzt werden oder zur bildgebenden Darstellung von 
Plasmid DNA-Transfer durch biolumineszente Messung von Luziferase Aktivität am 
lebenden Tier. 
 
Krebsmodelle mit Wildtypzellen können für das Beurteilen neuer voll synthetischer 
nicht viraler Transportsysteme genutzt werden, wobei durch den Transfer von 
verschiedenen Luziferasen der funktionelle Transfer in die Zielzelle nachgewiesen 
werden kann. Für den DNA-Transfer wurde ein biologisch abbaubares 
Polypropylenimindendrimer Generation 3, welches mit dem verzweigten 
Oligoethylenimin 800Da (G3HDOEI) modifiziert wurde, benutzt. 
 
64 
 
Chapter 6: Zusammenfassung 
 
 
In dieser Arbeit konnte gezeigt werden, dass neuartige Plasmide, die für Firefly und 
Gaussia Luziferase kodieren, für die Nachverfolgung von Metastasen in lebenden 
Tieren geeignet sind.  
 
Der große Vorteil von syngenen Krebsmodellen ist, dass die Mäuse ein intaktes 
Immunsystem haben, was es ermöglicht neue Transportsysteme direkt auf ihre 
Interaktionen mit dem Immunsystem hin zu beobachten. 
 
Zusätzlich wurde die etablierte Methode der Milzinjektion dazu genutzt ein 
Xenograftmodel mit der humanen Kolonkarzinomzelllinie LS174T in Firefly Luciferase 
stabil exprimierender Form zu entwickeln, welches zu Lebermetastasen führt. 
 
Xenograft als auch syngene Krebsmodelle, wurden für das Beobachten von 
Krebswachstum und dessen Verteilung in vivo, als auch für die Verfolgung von nicht 
viralen Gentransfer genutzt und das sowohl in experimentellen 
Lebermetastasenmodellen als auch im intravenösen Metastasenmodel. 
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